A GLP-Compliant Toxicology and Biodistribution Study: Systemic Delivery of an rAAV9 Vector for the Treatment of Mucopolysaccharidosis IIIB
| Autor: | Douglas M. McCarty, Christopher Shilling, Brad Bolon, William G. Bremer, Christopher M. Walker, Kimberly Zaraspe, Aaron S. Meadows, Chrystal L. Montgomery, Haiyan Fu, Kevin M. Flanigan, F. Jason Duncan, Kathryn Waligura, Marybeth Camboni, Bartholomew J. Naughton, Kim L. McBride |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
Pathology medicine.medical_specialty Biodistribution Transgene Mucopolysaccharidosis Genetic Vectors Endogeny Gene delivery Pharmacology Mice Mucopolysaccharidosis III Acetylglucosaminidase Lysosomal storage disease Animals Medicine Chronic toxicity Research Articles Genetics (clinical) business.industry Brain Genetic Therapy Dependovirus medicine.disease Mice Inbred C57BL Liver Spinal Cord Organ Specificity Practice Guidelines as Topic business |
| Zdroj: | Human Gene Therapy Clinical Development. 26:228-242 |
| ISSN: | 2324-8645 2324-8637 |
| Popis: | No treatment is currently available for mucopolysaccharidosis (MPS) IIIB, a neuropathic lysosomal storage disease due to defect in α-N-acetylglucosaminidase (NAGLU). In preparation for a clinical trial, we performed an IND-enabling GLP-toxicology study to assess systemic rAAV9-CMV-hNAGLU gene delivery in WT C57BL/6 mice at 1 × 10(14) vg/kg and 2 × 10(14) vg/kg (n = 30/group, M:F = 1:1), and non-GLP testing in MPS IIIB mice at 2 × 10(14) vg/kg. Importantly, no adverse clinical signs or chronic toxicity were observed through the 6 month study duration. The rAAV9-mediated rNAGLU expression was rapid and persistent in virtually all tested CNS and somatic tissues. However, acute liver toxicity occurred in 33% (5/15) WT males in the 2 × 10(14) vg/kg cohort, which was dose-dependent, sex-associated, and genotype-specific, likely due to hepatic rNAGLU overexpression. Interestingly, a significant dose response was observed only in the brain and spinal cord, whereas in the liver at 24 weeks postinfection (pi), NAGLU activity was reduced to endogenous levels in the high dose cohort but remained at supranormal levels in the low dose group. The possibility of rAAV9 germline transmission appears to be minimal. The vector delivery resulted in transient T-cell responses and characteristic acute antibody responses to both AAV9 and rNAGLU in all rAAV9-treated animals, with no detectable impacts on tissue transgene expression. This study demonstrates a generally safe and effective profile, and may have identified the upper dosing limit of rAAV9-CMV-hNAGLU via systemic delivery for the treatment of MPS IIIB. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|